CN1320886C - 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途 - Google Patents

安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途 Download PDF

Info

Publication number
CN1320886C
CN1320886C CNB038112299A CN03811229A CN1320886C CN 1320886 C CN1320886 C CN 1320886C CN B038112299 A CNB038112299 A CN B038112299A CN 03811229 A CN03811229 A CN 03811229A CN 1320886 C CN1320886 C CN 1320886C
Authority
CN
China
Prior art keywords
zonisamide
anticonvulsant
amfebutamone
weight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038112299A
Other languages
English (en)
Chinese (zh)
Other versions
CN1652778A (zh
Inventor
K·M·加德
K·R·R·克里希南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of CN1652778A publication Critical patent/CN1652778A/zh
Application granted granted Critical
Publication of CN1320886C publication Critical patent/CN1320886C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038112299A 2002-05-17 2003-05-19 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途 Expired - Lifetime CN1320886C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38087402P 2002-05-17 2002-05-17
US60/380,874 2002-05-17

Publications (2)

Publication Number Publication Date
CN1652778A CN1652778A (zh) 2005-08-10
CN1320886C true CN1320886C (zh) 2007-06-13

Family

ID=29550030

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038112299A Expired - Lifetime CN1320886C (zh) 2002-05-17 2003-05-19 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途

Country Status (11)

Country Link
US (7) US7109198B2 (es)
EP (3) EP1505967B1 (es)
JP (1) JP4545584B2 (es)
KR (2) KR101072885B1 (es)
CN (1) CN1320886C (es)
AU (1) AU2003231788B2 (es)
CA (1) CA2483464C (es)
HK (1) HK1074778A1 (es)
MX (1) MXPA04011203A (es)
RU (1) RU2341259C2 (es)
WO (1) WO2003097046A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
EP1505967B1 (en) 2002-05-17 2016-07-13 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20190262318A1 (en) * 2002-05-17 2019-08-29 Duke University Method for Treating Obesity
US20190290618A1 (en) * 2002-05-17 2019-09-26 Duke University Method for Treating Obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
SE0400378D0 (sv) * 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
US20060153934A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and magnesium
WO2006130522A2 (en) * 2005-05-31 2006-12-07 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US8492432B2 (en) 2005-08-17 2013-07-23 Hill's Pet Nutrition, Inc. Methods for the treatment of kidney disease
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
WO2007047351A2 (en) * 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TWI425944B (zh) * 2005-11-28 2014-02-11 Orexigen Therapeutics Inc 唑尼沙胺（ｚｏｎｉｓａｍｉｄｅ）之持續釋放調配物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8088786B2 (en) * 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
WO2009152152A1 (en) * 2008-06-09 2009-12-17 Amarillo Biosciences, Inc. Treatment of obesity with an interferon
US8114445B2 (en) * 2008-11-07 2012-02-14 Reliv International Inc. Dietary supplement for promoting wellness and weight loss and methods of administering the same
EP2381796B1 (en) * 2008-12-30 2019-02-20 Hill's Pet Nutrition, Inc. Compositions and methods for treating and preventing weight-related disorders in companion animals
US8383638B2 (en) * 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
WO2011163231A2 (en) 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
KR20140054066A (ko) 2011-07-15 2014-05-08 뉴서트 사이언시스, 인크. 대사 경로 조절을 위한 조성물 및 방법
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
EP2919772B1 (en) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
AU2014207707B2 (en) 2013-01-15 2018-11-01 Nusirt Sciences, Inc. Treating pulmonary conditions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
MX2015011195A (es) 2013-03-15 2016-03-11 Nusirt Sciences Inc La leucina y el acido nicotinico reducen los niveles de lipidos.
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CN1224352A (zh) * 1996-06-28 1999-07-28 奥索·麦克尼尔药品公司 用于治疗肥胖的抗惊厥剂氨基磺酸酯衍生物
WO2001026641A2 (en) * 1999-10-13 2001-04-19 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
CN1294513A (zh) * 1998-01-21 2001-05-09 葛兰素集团有限公司 医药活性的吗啉醇

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US181070A (en) * 1876-08-15 Improvement in burglar-proof gratings
US100205A (en) * 1870-02-22 Improvement in furnaces
US277579A (en) * 1883-05-15 Axle-skein
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US9514A (en) * 1853-01-04 Improvement in self-winding telegraphic registers
US55008A (en) * 1866-05-22 Improved clothes-sprinkler
US142290A (en) * 1873-08-26 Improvement in trimming attachments for sewing-machines
US122033A (en) * 1871-12-19 Improvement in rotary engines
US154002A (en) * 1874-08-11 Improvement in electric telegraphs
US2462A (en) * 1842-02-21 Worked buttons on the heads
US144174A (en) * 1873-10-28 Improvement in steam-engine valve-gears
US254208A (en) * 1882-02-28 Geoegb e
US79501A (en) * 1868-06-30 Jambs righey
US58293A (en) * 1866-09-25 Improved lady s-saddle tree
US137144A (en) * 1873-03-25 Improvement in stop-cocks
US215552A (en) * 1879-05-20 Improvement in gar-couplings
US143322A (en) * 1873-09-30 blake
US106576A (en) * 1870-08-23 Improvement in washing-machines
US26986A (en) * 1860-01-31 Mortising-machine
US160750A (en) * 1875-03-16 Improvement in grain-separators
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US4089855A (en) * 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4689332A (en) * 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
NL8800823A (nl) * 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
WO1990013294A1 (en) 1989-05-09 1990-11-15 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
FR2657350B1 (fr) 1990-01-19 1992-05-15 Centre Nat Rech Scient Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ATE214276T1 (de) 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5713488A (en) * 1996-01-24 1998-02-03 Farrugia; John V. Condom dispenser
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatment using naltrexone and related compounds
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CN1155410C (zh) * 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
ES2244103T3 (es) * 1997-12-26 2005-12-01 Dainippon Pharmaceutical Co., Ltd. Remedio para enfermedades neurodegenerativas.
AU2483599A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) * 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6323236B2 (en) 1999-02-24 2001-11-27 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
WO2000059851A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
ES2242175T3 (es) * 1999-07-01 2005-11-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la fibromialgia y otros trastornos somatoformes.
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CN1406129A (zh) * 2000-01-22 2003-03-26 艾伯特·舒尔曼 用于治疗物质滥用的方法
US20020090615A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
ATE326222T1 (de) * 2000-03-15 2006-06-15 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6627653B2 (en) * 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
ES2310192T3 (es) * 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
BR0115055A (pt) * 2000-10-30 2003-12-30 Ortho Mcneil Pharm Inc Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US6481031B1 (en) * 2001-11-14 2002-11-19 In Mo Hwang Pillow oriented for comfort in varying sleeping positions
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
EP1505967B1 (en) 2002-05-17 2016-07-13 Duke University Method for treating obesity
US20050215552A1 (en) 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP2005533849A (ja) 2002-07-18 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド 肥満治療のための組み合わせ療法
US7273884B2 (en) 2002-09-13 2007-09-25 Eisai, Inc. Method of treating tremors
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
US20060148721A1 (en) 2003-06-06 2006-07-06 Erondu Ngozi E Combination therapy for the treatment of dyslipidemia
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
KR100965580B1 (ko) * 2003-08-21 2010-06-23 엘지디스플레이 주식회사 액정표시장치와 그의 구동방법
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US7429580B2 (en) 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060160750A1 (en) 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005107806A1 (en) 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
RU2006139930A (ru) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
EP1773308A1 (en) 2004-08-03 2007-04-18 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US7346233B2 (en) * 2005-02-14 2008-03-18 Corning Incorporated Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
CN1224352A (zh) * 1996-06-28 1999-07-28 奥索·麦克尼尔药品公司 用于治疗肥胖的抗惊厥剂氨基磺酸酯衍生物
CN1294513A (zh) * 1998-01-21 2001-05-09 葛兰素集团有限公司 医药活性的吗啉醇
WO2001026641A2 (en) * 1999-10-13 2001-04-19 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity

Also Published As

Publication number Publication date
US20040198668A1 (en) 2004-10-07
US20040033965A1 (en) 2004-02-19
EP3173082A1 (en) 2017-05-31
RU2004131636A (ru) 2005-06-27
US7109198B2 (en) 2006-09-19
CN1652778A (zh) 2005-08-10
EP1505967B1 (en) 2016-07-13
JP2005530782A (ja) 2005-10-13
CA2483464A1 (en) 2003-11-27
KR101072885B1 (ko) 2011-10-17
AU2003231788A1 (en) 2003-12-02
WO2003097046A1 (en) 2003-11-27
US7754748B2 (en) 2010-07-13
US20050143322A1 (en) 2005-06-30
US20080188476A1 (en) 2008-08-07
RU2341259C2 (ru) 2008-12-20
KR20050023265A (ko) 2005-03-09
HK1074778A1 (zh) 2005-11-25
EP1505967A4 (en) 2007-09-05
US20080319036A1 (en) 2008-12-25
MXPA04011203A (es) 2005-07-14
US20060009514A1 (en) 2006-01-12
EP2301537A1 (en) 2011-03-30
JP4545584B2 (ja) 2010-09-15
US20050137144A1 (en) 2005-06-23
CA2483464C (en) 2011-12-20
US7425571B2 (en) 2008-09-16
KR20110043664A (ko) 2011-04-27
EP1505967A1 (en) 2005-02-16
AU2003231788B2 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
CN1320886C (zh) 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
Weintraub et al. Sibutramine in weight control: a dose‐ranging, efficacy study
US20150320726A1 (en) Method for treating obesity
US20220226262A1 (en) Methods of treating doose syndrome using fenfluramine
Gadde et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
AU2017202793B2 (en) Methods for Reducing Binge or Compulsive Eating
Xiong et al. Combination phentermine/topiramate for obesity treatment in primary care: a review
US20190290618A1 (en) Method for Treating Obesity
US20190262318A1 (en) Method for Treating Obesity
RU2784524C2 (ru) Способы лечения синдрома дузе с использованием фенфлурамина
RU2561583C2 (ru) Фармацевтическая композиция для лечения и/или предупреждения нарушений, связанных с ожирением, и способ лечения и/или предупреждения нарушений, связанных с ожирением
Bar Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity
Haq et al. Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence?
Chlup et al. Contradictory reviews of experts to assess drunkenness and/or hypoglycaemia in a type 1 diabetic driver

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070613